Stay updated on Dupilumab in Prurigo Nodularis: Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in Prurigo Nodularis: Clinical Trial page.

Latest updates to the Dupilumab in Prurigo Nodularis: Clinical Trial page
- Check6 days agoChange DetectedThe record provides details of Sanofi’s completed Phase 3 study evaluating dupilumab versus placebo for prurigo nodularis, including its study plan, participant criteria, and outcome measures. It also includes study documents, publications, and record history.SummaryDifference92%

- Check13 days agoChange DetectedThe footer revision number changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAn NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page, and the displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe site's displayed revision identifier changes from v3.7.0 to v3.7.1 while the study page remains inaccessible with a 403 error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the previous study details and navigation. This prevents access to the study record and its associated information.SummaryDifference20%

- Check62 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, reflecting a software update to the ClinicalTrials.gov page. This change does not alter the study details, eligibility criteria, or results presented on the page.SummaryDifference0.0%

Stay in the know with updates to Dupilumab in Prurigo Nodularis: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in Prurigo Nodularis: Clinical Trial page.